Dicot (DICOT) Q4 2024 earnings summary

Executive summary

• No net sales reported for Q4 or full year 2024; company remains pre-commercial.

• Net loss after financial items was SEK -20.8 million for Q4 (vs. -15.7 million YoY) and SEK -57.7 million for the year (vs. -44.2 million YoY).

• LIB-01 phase 1 clinical trial completed with positive safety and efficacy signals; phase 2a initiated on schedule in Q4 2024.

• Nasdaq First North Growth Market listing completed in November 2024, enhancing visibility and access to capital.

• Strong financial position following a SEK 135 million rights issue in August 2024, oversubscribed at 124%.

Financial highlights

• Net sales: SEK 0.0 million for Q4 and full year 2024 (unchanged YoY).

• Net loss after financial items: SEK -20.8 million for Q4 (vs. -15.7 million YoY); SEK -57.7 million for full year (vs. -44.2 million YoY).

• Earnings per share: SEK -0.01 for Q4 (vs. -0.02 YoY); SEK -0.05 for full year (vs. -0.08 YoY).

• Operating expenses increased to SEK 21.7 million in Q4 (vs. 16.5 million YoY), mainly due to phase 2a study start.

• Cash and cash equivalents at year-end: SEK 113.4 million (vs. 47.3 million YoY).

Outlook and guidance

• Phase 2a clinical study for LIB-01 ongoing, with over half of 140 participants dosed; results expected mid-2025.

• Proceeds from TO6 warrants (exercise in March 2025) expected to fund phase 2b and portfolio expansion.

• Continued focus on erectile dysfunction, with parallel preclinical work on metabolic diseases.

• No dividend proposed for 2024.